Literature DB >> 14583742

Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray.

Cristina Ferreira Netto1, Francisco Silveira Guimarães.   

Abstract

Systemic administration of cholecystokinin (CCK) fragments produces anxiogenic effects. The dorsal periaqueductal gray (dPAG) has been related to anxiety and panic reactions. The objective of this study was to investigate a possible anxiogenic effect of CCK-8 microinjected into the dPAG. At 10 min after the last microinjection (0.5 microl) into the dPAG male Wistar rats (N=7-17) were tested in the elevated plus-maze, an animal model of anxiety. The following treatments were tested alone or in combination: sulfated CCK-8 (CCK-8s, 0.5-1 microg), PD 135158 (N-methyl-D-glucamine, 0.1 microg), a CCK-2 receptor antagonist, lorglumide (0.1-0.3 microg), a CCK-1 receptor antagonist. In addition, Fos immunohistochemistry was performed in rats (n=3-4) treated with CCK-8s (1 microg) alone or in combination with PD 135158 (0.1 microg). CCK-8s produced anxiogenic-like effect, decreasing the percentage of time spent in open arm (saline=30.3+/-6.6, CCK 0.5 microg=15.2+/-1.8; CCK 1 microg=14.6+/-2.1). This effect was prevented by pretreatment with PD 135158, but not by lorglumide. CCK-8s injected into the dPAG induced Fos immunoreactivity in several brain areas related to defensive behavior, including the PAG, median, and dorsal raphe nuclei, superior colliculus, lateral septal nuclei, medial hypothalamus, and medial amygdala. This effect was also prevented by pretreatment with PD 135,158. These results suggest that CCK-8s, acting on CCK-2 receptors, may modulate anxiety reactions in the dPAG.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14583742     DOI: 10.1038/sj.npp.1300334

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  7 in total

1.  Social defeat, a paradigm of depression in rats that elicits 22-kHz vocalizations, preferentially activates the cholinergic signaling pathway in the periaqueductal gray.

Authors:  Roger A Kroes; Jeffrey Burgdorf; Nigel J Otto; Jaak Panksepp; Joseph R Moskal
Journal:  Behav Brain Res       Date:  2007-03-25       Impact factor: 3.332

Review 2.  The age of anxiety: role of animal models of anxiolytic action in drug discovery.

Authors:  John F Cryan; Fabian F Sweeney
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Cholecystokinin exerts an effect via the endocannabinoid system to inhibit GABAergic transmission in midbrain periaqueductal gray.

Authors:  Vanessa A Mitchell; Hyo-Jin Jeong; Geoffrey M Drew; Christopher W Vaughan
Journal:  Neuropsychopharmacology       Date:  2011-04-27       Impact factor: 7.853

4.  Sparse genetically defined neurons refine the canonical role of periaqueductal gray columnar organization.

Authors:  Mimi Q La-Vu; Ekayana Sethi; Sandra Maesta-Pereira; Peter J Schuette; Brooke C Tobias; Fernando M C V Reis; Weisheng Wang; Anita Torossian; Amy Bishop; Saskia J Leonard; Lilly Lin; Catherine M Cahill; Avishek Adhikari
Journal:  Elife       Date:  2022-06-08       Impact factor: 8.713

Review 5.  The Periaqueductal Gray and Its Extended Participation in Drug Addiction Phenomena.

Authors:  Priscila Vázquez-León; Abraham Miranda-Páez; Jesús Chávez-Reyes; Gonzalo Allende; Paulino Barragán-Iglesias; Bruno A Marichal-Cancino
Journal:  Neurosci Bull       Date:  2021-07-24       Impact factor: 5.271

Review 6.  Fine-tuning of defensive behaviors in the dorsal periaqueductal gray by atypical neurotransmitters.

Authors:  M V Fogaça; S F Lisboa; D C Aguiar; F A Moreira; F V Gomes; P C Casarotto; F S Guimarães
Journal:  Braz J Med Biol Res       Date:  2012-03-08       Impact factor: 2.590

Review 7.  The Neuromodulatory Basis of Aggression: Lessons From the Humble Fruit Fly.

Authors:  Caroline B Palavicino-Maggio; Saheli Sengupta
Journal:  Front Behav Neurosci       Date:  2022-04-18       Impact factor: 3.617

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.